Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Panitumumab, Carboplatin, Paclitaxel, Intensity Modulated Radiation Therapy, 5-Fluorouracil, Docetaxel, Cisplatin; Drug · Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Leukemia
Interventions: Clofarabine, Idarubicin, Cytarabine, Fludarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Triple Negative Breast Cancer
Interventions: Paclitaxel, Carboplatin, Pembrolizumab, Doxorubicin, Cyclophosphamide, Personalized cancer vaccine (PCV), AB248, pVAC tools neoantigen prediction algorithm, poly-ICLC; Drug · Biological · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Small Cell Lung Cancer
Interventions: YL201, Tarlatamab, Durvalumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 11
States / cities: Irvine, California • New Haven, Connecticut • Tampa, Florida + 7 more

Conditions: Endometrial Cancer
Interventions: Navtemadlin, Navtemadlin Placebo; Drug
Lead sponsor: Kartos Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 19
States / cities: Vallejo, California • Atlanta, Georgia • Savannah, Georgia + 16 more

Conditions: Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, CD20+ Lymphoblastic Lymphoma, Follicular Lymphoma, Grade III
Interventions: Obinutuzumab, Liposomal ARA-C, Ifosfamide, Carboplatin, Etoposide; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 3 Years to 31 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Leukemia, Myeloid, Acute
Interventions: Decitabine 20 mg/m^2, Talacotuzumab 9 mg/kg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 65 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 11
States / cities: Orange, California • Aurora, Colorado • New Orleans, Louisiana + 8 more

Conditions: Prostate Cancer
Interventions: Questionaires, fMRI scan (optional); Behavioral · Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 65 Years and older · Male only
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2027
U.S. locations: 2
States / cities: Duarte, California • New York, New York

Conditions: Chronic Pain
Interventions: WHT; Other
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Lung Cancer Screening
Interventions: Sybil Artificial Intelligence (AI) screening; Diagnostic Test
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 50 Years to 80 Years
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2038
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Healthy Volunteer
Interventions: Ro542-4802/F03 (Reference), Ro542-4802/F07 (Test), Ro542-4802/F08 (Test), Ro542-4802/F14 (Test); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Bacterial Infections
Interventions: RO7223280; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Sarasota, Florida • Louisville, Kentucky • Royal Oak, Michigan + 2 more

Conditions: Ovarian Cancer
Interventions: Mirvetuximab Soravtansine, Bevacizumab, Carboplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 31
States / cities: La Jolla, California • Solvang, California • Gainesville, Florida + 28 more

Conditions: Advanced Non Small Cell Lung Cancer
Interventions: Part A - AZD9291 in combination with AZD6094, Part A - AZD9291 in combination with continuous selumetinib (Asian subjects), Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects), Part A - AZD9291 in combination with intermittent selumetinib, Part A - AZD9291 in combination with MEDI4736, Part B - AZD9291 in combination with AZD6094, Part B - AZD9291 in combination with selumetinib, Part B - AZD9291 in combination with MEDI4736, Part C - AZD6094 monotherapy (Japan only), Part C - AZD9291 in combination with AZD6094 (Japan only), Part D - AZD9291 in combination with AZD6094; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 6
States / cities: Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more

Conditions: HIV-1-infection
Interventions: ibalizumab-uiyk; Drug
Lead sponsor: TaiMed Biologics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Los Angeles, California • Fort Lauderdale, Florida • Orlando, Florida + 1 more

Conditions: Metastatic Cancer
Interventions: LY3007113; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Santa Monica, California • San Antonio, Texas

Conditions: Impulse Control Disorder
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS); Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 21 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Solid Tumors
Interventions: INCB099280, adagrasib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Greeley, Colorado • Detroit, Michigan + 2 more

Conditions: Alzheimer's Disease
Interventions: LY2811376, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Multiple Sclerosis, Neuropathic Pain
Interventions: glibenclamide, Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Graft Versus Host Disease, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
Interventions: thiotepa, cyclophosphamide, tacrolimus, methotrexate, sirolimus, total body irradiation; Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 44
States / cities: Phoenix, Arizona • Duarte, California • Oakland, California + 40 more

Conditions: Follicular Lymphoma (FL)
Interventions: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/Prenisolone; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 733 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Plantation, Florida • Noblesville, Indiana • Wichita, Kansas + 6 more

Conditions: Healthy
Interventions: P7435, Placebo; Drug · Other
Lead sponsor: Piramal Enterprises Limited; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Infections, Bacterial
Interventions: GSK1322322; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Buffalo, New York

Search by objective public record fields.

Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck

Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome

Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older

Effect of Wearable Health Technology on Patients Treated for Chronic Pain at Geisinger Health System

LUNG-07: Advancing Precision-Based Lung Cancer Screening: Implementation, AI-Guided Risk Stratification, and Biomarker Integration (CREST AI)

A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers

A Study to Investigate the Pharmacokinetics of RO7223280 in Critically Ill Participants With Bacterial Infections

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection

A Study of LY3007113 in Participants With Advanced Cancer

Feasibility of Accelerated, Personalized rTMS as an Adjuvant for Impulse Control Disorders: a Pilot Study

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation

A Safety Study of LY2811376 Single Doses in Healthy Subjects

OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis

Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects

Relative Bioavailability Study in Healthy Subjects